Voluntary Worldwide Withdrawal of VIOXX

Merck announced on September 30, 2004 a worldwide withdrawal of its anti-inflammatory drug, VIOXX, following information that people taking VIOXX are twice as likely to have heart attacks and strokes as people who take older inflammatory drugs, such as Naproxen.

The VIOXX recall culminates mounting concern beginning in early 2001, that VIOXX might cause serious cardiovascular events.

Ricci~Leopold is available to assist you in evaluating and prosecuting VIOXX claims involving individuals who, while taking VIOXX suffered a heart attack, stroke or other severe cardiac injury, including death.

If you believe that you or a loved one has been adversely affected by VIOXX, please fill out an evaluation form. Provide as much information as possible to speed the processing of your inquiry.

Ricci~Leopold is here to assist you with any communication needs that will help get this important, timely information to the general public.

Please call Meg Sadaka at (800)699-1914 with any questions you may have.

Related information on - Bextra - Celebrex.

BREAKING NEWS:

Congressional Hearings:

• 11/18/2004 Testimony before Committee on Finance, United States Senate:
  • Sandra Kweder, M.D., Deputy Director, Office of New Drugs
  • Raymond V. Gilmartin, President, Chairman and Chief Executive Officer, Merck and Co., Inc

Merck (VIOXX) Information:

• Vioxx Timeline Key Dates for VIGOR and Long-term Placebo-Controlled Studies... (PDF)
• Timeline of Epidemiological Studies Involving VIOXX and NSAIDS (PDF)
• Overview Chart of Major VIOXX Research Studies (PDF)
• Vioxx
• Known Side Effects

FDA Information:

• FDA News
• 9/30/2004 Study Report (PDF)
• 11/10/2004 Drug Regulation in Controversy - Vioxx

Press Releases:

• 10/7/2004 Local Attorney Impacted by Vioxx
• 9/30/2004 Public Citizen - Vioxx, Other "Super Aspirins" Are Super Disasters - Other Cox-2 Alternatives Have Safety Problems Too
• 9/30/2004 Merck Announces Voluntary Worldwide Withdrawal of Vioxx

News Coverage:

• 11/14/2004 Despite Warnings, Drug Giant Took Long Path to Vioxx Recall
• 10/21/2004 New England Journal of Medicine: Failing the Public Health - VIOXX (Rofecoxib), Merck, and the FDA
• 10/21/2004 New England Journal of Medicine: Coxibs and Cardiovascular Disease